Prelude Therapeutics Inc
PRLD0.828USD
0.000
交易中 （美東）報價延遲15分鐘
46.76M總市值
虧損本益比TTM
關於 Prelude Therapeutics Inc 公司
Prelude Therapeutics Incorporated 是一家臨牀階段的完全整合腫瘤學公司，以藥物發現爲基礎，爲醫療資源匱乏的患者提供新型精準抗癌藥物。該公司開發了由多個不同項目組成的多樣化產品線：激酶、靶向蛋白降解劑和精準抗體藥物偶聯物。其候選產品包括 PRT3789、PRT2527 和 PRT3645。PRT3789 是一種高度選擇性的 SMARCA2 蛋白降解劑，與 SMARCA4 一起通過染色質重塑控制基因調控。其 CDK9 項目是癌症促進轉錄程序的重要調節器，包括由 MCL1、MYC 和 MYB 驅動的轉錄程序。PRT3645 是一種腦和組織滲透分子，可有效靶向 CDK4/6，對 CDK4 具有偏向選擇性。PRT2527 旨在成爲一種強效且選擇性的 CDK9 抑制劑。其 MCL1 候選藥物 PRT1419 旨在成爲抗凋亡蛋白 MCL1 的強效選擇性抑制劑。
公司簡介
公司代碼PRLD
公司名稱Prelude Therapeutics Inc
上市日期Sep 25, 2020
CEODr. Krishna (Kris) Vaddi, Ph.D.
員工數量131
證券類型Ordinary Share
年結日Sep 25
公司地址175 Innovation Boulevard
城市WILMINGTON
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編19805
電話13024671280
網址https://preludetx.com/
公司代碼PRLD
上市日期Sep 25, 2020
CEODr. Krishna (Kris) Vaddi, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
+29.33%
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+27.99%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
185.69K
+2.77%
Dr. Jane Huang, M.D.
Dr. Jane Huang, M.D.
President, Chief Medical Officer
President, Chief Medical Officer
90.27K
+7.15%
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
10.00K
--
Dr. Paul Scherer, M.D.
Dr. Paul Scherer, M.D.
Independent Director
Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Independent Director
Independent Director
--
--
Mr. Bryant D. Lim, J.D.
Mr. Bryant D. Lim, J.D.
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
+29.33%
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+27.99%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
185.69K
+2.77%
Dr. Jane Huang, M.D.
Dr. Jane Huang, M.D.
President, Chief Medical Officer
President, Chief Medical Officer
90.27K
+7.15%
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
10.00K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月27日 週日
更新時間: 7月27日 週日
持股股東
股東類型
持股股東
持股股東
佔比
OrbiMed Advisors, LLC
25.02%
Baker Bros. Advisors LP
23.20%
Vaddi (Krishna)
8.41%
Boxer Capital Management, LLC
4.83%
The Vanguard Group, Inc.
2.31%
Other
36.22%
持股股東
持股股東
佔比
OrbiMed Advisors, LLC
25.02%
Baker Bros. Advisors LP
23.20%
Vaddi (Krishna)
8.41%
Boxer Capital Management, LLC
4.83%
The Vanguard Group, Inc.
2.31%
Other
36.22%
股東類型
持股股東
佔比
Hedge Fund
31.09%
Private Equity
25.02%
Individual Investor
11.38%
Investment Advisor
9.38%
Investment Advisor/Hedge Fund
3.57%
Research Firm
0.70%
Venture Capital
0.06%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
18.77%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
158
35.42M
81.22%
-13.38M
2025Q1
169
35.41M
81.20%
-13.64M
2024Q4
176
41.97M
99.49%
-4.74M
2024Q3
176
39.67M
94.09%
-11.21M
2024Q2
173
43.50M
103.37%
-2.47M
2024Q1
184
38.12M
90.60%
-8.41M
2023Q4
190
38.61M
71.39%
-9.45M
2023Q3
202
40.53M
76.60%
-4.90M
2023Q2
201
43.54M
105.11%
+2.58M
2023Q1
203
37.45M
102.57%
-2.14M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
OrbiMed Advisors, LLC
10.91M
25.02%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
10.12M
23.2%
-5.19K
-0.05%
Jun 12, 2025
Vaddi (Krishna)
3.67M
8.41%
+832.02K
+29.33%
Mar 31, 2025
Boxer Capital Management, LLC
2.11M
4.83%
+399.83K
+23.41%
Mar 31, 2025
The Vanguard Group, Inc.
1.01M
2.31%
-1.19K
-0.12%
Mar 31, 2025
T. Rowe Price Associates, Inc.
959.30K
2.2%
-53.05K
-5.24%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
919.00K
2.11%
-14.36K
-1.54%
Mar 31, 2025
Renaissance Technologies LLC
656.70K
1.51%
+22.20K
+3.50%
Mar 31, 2025
Acadian Asset Management LLC
529.33K
1.21%
+43.95K
+9.05%
Mar 31, 2025
Friedman (Paul A)
500.10K
1.15%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
Schwab U.S. Small-Cap ETF
0%
Schwab U.S. Broad Market ETF
0%
iShares Micro-Cap ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
查看更多
Dimensional US Core Equity 1 ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
ProShares UltraPro Russell2000
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
Schwab U.S. Small-Cap ETF
佔比0%
Schwab U.S. Broad Market ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
Invesco Nasdaq Biotechnology ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
